🚀 VC round data is live in beta, check it out!
Castle Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Castle Biosciences and similar public comparables like Lunit, Jiangsu Bioperfectus, OPKO Health, Personalis and more.
Castle Biosciences Overview
About Castle Biosciences
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Founded
2007
HQ
Employees
761
Website
Financials (LTM)
EV
$575M
Castle Biosciences Financials
Castle Biosciences reported last 12-month revenue of $345M and EBITDA of $36M.
In the same LTM period, Castle Biosciences generated $263M in gross profit, $36M in EBITDA, and had net loss of ($27M).
Revenue (LTM)
Castle Biosciences P&L
In the most recent fiscal year, Castle Biosciences reported revenue of $344M and EBITDA of $43M.
Castle Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $345M | XXX | $344M | XXX | XXX | XXX |
| Gross Profit | $263M | XXX | $273M | XXX | XXX | XXX |
| Gross Margin | 76% | XXX | 79% | XXX | XXX | XXX |
| EBITDA | $36M | XXX | $43M | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | 13% | XXX | XXX | XXX |
| EBIT Margin | (13%) | XXX | (12%) | XXX | XXX | XXX |
| Net Profit | ($27M) | XXX | ($24M) | XXX | XXX | XXX |
| Net Margin | (8%) | XXX | (7%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Castle Biosciences Stock Performance
Castle Biosciences has current market cap of $838M, and enterprise value of $575M.
Market Cap Evolution
Castle Biosciences' stock price is $28.17.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $575M | $838M | 0.0% | XXX | XXX | XXX | $-0.81 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCastle Biosciences Valuation Multiples
Castle Biosciences trades at 1.7x EV/Revenue multiple, and 15.8x EV/EBITDA.
EV / Revenue (LTM)
Castle Biosciences Financial Valuation Multiples
As of April 7, 2026, Castle Biosciences has market cap of $838M and EV of $575M.
Equity research analysts estimate Castle Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Castle Biosciences has a P/E ratio of (30.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $838M | XXX | $838M | XXX | XXX | XXX |
| EV (current) | $575M | XXX | $575M | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 15.8x | XXX | 13.3x | XXX | XXX | XXX |
| EV/EBIT | (13.3x) | XXX | (13.4x) | XXX | XXX | XXX |
| EV/Gross Profit | 2.2x | XXX | 2.1x | XXX | XXX | XXX |
| P/E | (30.9x) | XXX | (34.7x) | XXX | XXX | XXX |
| EV/FCF | 25.2x | XXX | 20.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Castle Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Castle Biosciences Margins & Growth Rates
Castle Biosciences' revenue in the last 12 month grew by 4%.
Castle Biosciences' revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.4M for the same period.
Castle Biosciences' rule of 40 is 6% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Castle Biosciences' rule of X is 6% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Castle Biosciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | (33%) | XXX | (59%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 6% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 6% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 40% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 26% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 15% | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 92% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Castle Biosciences Public Comps
See public comps and valuation multiples for other Diagnostics & Genomics and Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Lunit | XXX | XXX | XXX | XXX | XXX | XXX |
| Jiangsu Bioperfectus | XXX | XXX | XXX | XXX | XXX | XXX |
| OPKO Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Personalis | XXX | XXX | XXX | XXX | XXX | XXX |
| Mirxes Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Castle Biosciences M&A Activity
Castle Biosciences acquired XXX companies to date.
Last acquisition by Castle Biosciences was on XXXXXXXX, XXXXX. Castle Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Castle Biosciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCastle Biosciences Investment Activity
Castle Biosciences invested in XXX companies to date.
Castle Biosciences made its latest investment on XXXXXXXX, XXXXX. Castle Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Castle Biosciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Castle Biosciences
| When was Castle Biosciences founded? | Castle Biosciences was founded in 2007. |
| Where is Castle Biosciences headquartered? | Castle Biosciences is headquartered in United States. |
| How many employees does Castle Biosciences have? | As of today, Castle Biosciences has over 761 employees. |
| Who is the CEO of Castle Biosciences? | Castle Biosciences' CEO is Derek J. Maetzold. |
| Is Castle Biosciences publicly listed? | Yes, Castle Biosciences is a public company listed on Nasdaq. |
| What is the stock symbol of Castle Biosciences? | Castle Biosciences trades under CSTL ticker. |
| When did Castle Biosciences go public? | Castle Biosciences went public in 2019. |
| Who are competitors of Castle Biosciences? | Castle Biosciences main competitors are Lunit, Jiangsu Bioperfectus, OPKO Health, Personalis. |
| What is the current market cap of Castle Biosciences? | Castle Biosciences' current market cap is $838M. |
| What is the current revenue of Castle Biosciences? | Castle Biosciences' last 12 months revenue is $345M. |
| What is the current revenue growth of Castle Biosciences? | Castle Biosciences revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Castle Biosciences? | Current revenue multiple of Castle Biosciences is 1.7x. |
| Is Castle Biosciences profitable? | Yes, Castle Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Castle Biosciences? | Castle Biosciences' last 12 months EBITDA is $36M. |
| What is Castle Biosciences' EBITDA margin? | Castle Biosciences' last 12 months EBITDA margin is 11%. |
| What is the current EV/EBITDA multiple of Castle Biosciences? | Current EBITDA multiple of Castle Biosciences is 15.8x. |
| What is the current FCF of Castle Biosciences? | Castle Biosciences' last 12 months FCF is $23M. |
| What is Castle Biosciences' FCF margin? | Castle Biosciences' last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of Castle Biosciences? | Current FCF multiple of Castle Biosciences is 25.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.